Initiative initially funded by $10 million
grant from the Bill & Melinda Gates Foundation
Schr�dinger, Inc. (Nasdaq: SDGR), whose physics-based
computational platform is transforming the way therapeutics and
materials are discovered, today announced that it is embarking on
an initiative to expand its computational platform to predict
toxicology risk early in drug discovery. The goal of the initiative
is to develop a computational solution designed to improve the
properties of novel drug development candidates and reduce the risk
of development failure associated with binding to off-target
proteins, which can be associated with serious side effects. This
initiative is an expansion of Schr�dinger’s “predict first” digital
laboratory and will leverage its physics-based platform and
NVIDIA’s AI technologies. Broad deployment of predictive toxicology
has the potential to accelerate progress from target to drug
development candidate and reduce the risk of toxicity in
preclinical or clinical studies. Safety issues are a frequent cause
of drug development delays and failures and are the focus of the
U.S. Food and Drug Administration's Predictive Toxicology
Roadmap.
The initiative will be funded by a $10 million grant from the
Bill & Melinda Gates Foundation to accelerate the scientific
research underlying this initiative for the first year of the
project. Once developed, the technology will be available to the
Gates Foundation’s grantees around the world to help speed the
development of new drugs against diseases that disproportionately
affect people in low- and middle-income countries. These tools will
also be available to Schr�dinger’s software customers and will be
used to advance Schr�dinger’s proprietary drug discovery programs
and collaborations.
“Drug discovery is an extremely challenging endeavor, and
off-target toxicity is a significant cause of drug development
failure. The application of our technology, at scale against a
broad panel of known off-target proteins, has the potential to
prevent a significant number of these failures, reducing the
potential for safety issues in preclinical and clinical research,
and lowering the cost and risk of drug development. Advances in
structural biology and computer performance, coupled with the
increasing accuracy of our computational platform, gives us a
unique opportunity to address the need for high quality
computational models for predictive toxicology,” stated Ramy Farid,
Ph.D., chief executive officer at Schr�dinger. “We appreciate the
support from the Gates Foundation, which allows us to immediately
scale up our efforts advancing this initiative.”
“Optimizing the safety profile of drug candidates is one of the
most difficult challenges in drug discovery, and computational
approaches have the potential to revolutionize the way we discover
drugs by enabling the prediction of drug toxicity with
unprecedented accuracy and efficiency prior to clinical testing,”
stated Trevor Mundel, president, global health, at the Gates
Foundation. “Leveraging computation to predict the toxicological
risk of drug candidates could ultimately improve productivity
across the pharmaceutical industry and unlock major advances
against diseases that continue to plague low- and middle-income
countries.”
“With its world-leading physics-based platform, Schr�dinger has
spearheaded the last two decades of computational drug and
materials discovery,” said Kimberly Powell, vice president of
healthcare at NVIDIA. “Accelerated computing — which introduces
many orders of magnitude in discovery power — combined with
generative AI will enhance researchers’ abilities to tackle complex
scientific challenges like predictive toxicology, leading to
faster, more efficient and effective discovery cycles and
transformative medicines for patients.”
Schr�dinger has already generated several computational
predictive models of off-target drug activity. The company’s recent
advances characterizing the structure of safety-related proteins
such as hERG (recently published in Cell) and cytochrome P450
enzymes are examples of these efforts.
About Schr�dinger
Schr�dinger is transforming the way therapeutics and materials
are discovered. Schr�dinger has pioneered a physics-based
computational platform that enables discovery of high-quality,
novel molecules for drug development and materials applications
more rapidly and at lower cost compared to traditional methods. The
software platform is licensed by biopharmaceutical and industrial
companies, academic institutions, and government laboratories
around the world. Schr�dinger’s multidisciplinary drug discovery
team also leverages the software platform to advance a portfolio of
collaborative and proprietary programs to address unmet medical
needs.
Founded in 1990, Schr�dinger has approximately 850 employees and
is engaged with customers and collaborators in more than 70
countries. To learn more, visit www.schrodinger.com, follow us on
LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of 1995
including, but not limited to those statements regarding
Schr�dinger’s expectations about the speed and capacity of its
computational platform, the long-term potential of its business,
its ability to improve and advance the science underlying its
platform, including the ability to predict off-target activity, its
ability to improve drug discovery and the timing during which the
initiative’s technology will become available to software customers
and collaborators, as well as expectations related to the use of
its cash, cash equivalents and marketable securities. Statements
including words such as “aim,” “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,”
“intend,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and statements in
the future tense are forward-looking statements. These
forward-looking statements reflect Schr�dinger’s current views
about its plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to the company and on assumptions the company has made. Actual
results may differ materially from those described in these
forward-looking statements and are subject to a variety of
assumptions, uncertainties, risks and important factors that are
beyond Schr�dinger’s control, including the demand for its software
platform, its ability to further develop its computational
platform, its reliance upon third-party providers of cloud-based
infrastructure to host its software solutions, factors adversely
affecting the life sciences industry, fluctuations in the value of
the U.S. dollar and foreign currencies, its reliance upon its
third-party drug discovery collaborators, the uncertainties
inherent in drug development and commercialization, such as the
conduct of research activities and the timing of and its ability to
initiate and complete preclinical studies and clinical trials,
whether results from preclinical studies will be predictive of the
results of later preclinical studies and clinical trials,
uncertainties associated with the regulatory review of IND
submissions, clinical trials and applications for marketing
approvals, the ability to retain and hire key personnel and other
risks detailed under the caption “Risk Factors” and elsewhere in
the company’s Securities and Exchange Commission filings and
reports, including its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2024, filed with the Securities and
Exchange Commission on May 1, 2024, as well as future filings and
reports by the company. Any forward-looking statements contained in
this press release speak only as of the date hereof. Except as
required by law, Schr�dinger undertakes no duty or obligation to
update any forward-looking statements contained in this press
release as a result of new information, future events, changes in
expectations or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240726774411/en/
Jaren Madden Schr�dinger, Inc. (Investors) 617-266-6264
Matthew Luchini (Investors) Schr�dinger, Inc.
matthew.luchini@schrodinger.com 917-719-0636
Allie Nicodemo (Media) Schr�dinger, Inc.
allie.nicodemo@schrodinger.com 617-356-2325
Schrodinger (NASDAQ:SDGR)
過去 株価チャート
から 6 2024 まで 7 2024
Schrodinger (NASDAQ:SDGR)
過去 株価チャート
から 7 2023 まで 7 2024
